Noninvasive imaging of lupus nephritis disease activity
Search Results
You searched for: lupus nephritis
Results found: 1150
IL-2 and IL-33 as therapeutic agents for lupus nephritis
GMP-Ready Smith-Specific Regulatory T Cell Therapy to Treat Lupus Nephritis
Preclinical study
Novel treatments for lupus nephritis
Ptprz: A therapeutic target for Lupus Nephritis
Proliferative Lupus Nephritis
Inflammation of the kidneys caused by an autoimmune disease called systemic lupus erythematosus. The condition can cause hematuria and...
New Survey Shows Education and Communication Gaps in Lupus Nephritis Care
1 in 2 Lupus Nephritis Patients Don’t Know They Have Lupus
New York, NY– December 7, 2020. Significant gaps in...
Encouraging Results with Obinutuzumab for Lupus Nephritis
February 13, 2022
The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive...
Good News on Lupus Nephritis Discoveries from ACR Convergence 2020
November 19, 2020
The LRA is proud to share the extraordinary work presented at ACR Convergence 2020 by research members...
LRA-Supported Researchers Developed a Model to Predict Full-Blown Lupus Nephritis Down the Road
A new study funded by the Lupus Nephritis Trials Network with support from the Lupus Research Alliance has proposed...
LRA Statement: Potential Lupus Nephritis Drug Voclosporin Granted Priority Review by the U.S. FDA
NEW YORK, NY. July 22, 2020. The Lupus Research Alliance congratulates Aurinia Pharmaceuticals Inc. on acceptance of its NDA...
Lupus Research Alliance Pleased to Share Positive News about Potential Drug for Lupus Nephritis
NEW YORK, NY. June 11, 2019. The Lupus Research Alliance is pleased to share positive topline results from a...